Lion's Mane and the Immune System: What the Evidence Shows

By Peter Orpen, Co-Owner, Teelixir Updated: 27 March 2026 10 min read

Most people think of lion's mane as a brain mushroom. Focus. Memory. Cognition. That reputation is earned — the neurological research is compelling. But it obscures something equally interesting.

Lion's mane (Hericium erinaceus) has been examined across 215 published studies for immune-related effects — more than any other health area for this mushroom. The pattern that emerges is not "take this to fight a cold." It is more sophisticated than that.

The research points to a dual-action immune profile: compounds that can upregulate innate immune defences when the body needs them, and separate compounds that downregulate excessive inflammation when the immune system overshoots. We call this The Modulation Principle.

This article unpacks the mechanisms, the evidence quality, where the gaps are, and what it means practically for anyone considering lion's mane for immune support.

The Two Compound Families Driving Immune Activity

Understanding lion's mane's immune effects requires knowing which compounds do what. They fall into two distinct categories, extracted by different methods:

A 2025 systematic review (PMID: 40959699) examined the full spectrum of Hericium erinaceus bioactive compounds and confirmed anti-inflammatory, antioxidant, and anti-proliferative properties across multiple study models. This is not one isolated finding — it is a pattern across the literature.

How Mushroom Beta-Glucans Activate the Immune System

The immune story of lion's mane centres on its beta-glucan polysaccharides — but not just any beta-glucans. Mushroom beta-glucans have a (1,3)/(1,6) branching structure that differs from the (1,3)/(1,4) structure found in oats or barley. This structural difference matters biologically.

Your innate immune cells — particularly macrophages and dendritic cells — express a surface receptor called Dectin-1 that specifically recognises the fungal (1,3)/(1,6) beta-glucan structure. When Dectin-1 binds a mushroom beta-glucan, it triggers a signalling cascade:

• Macrophage activation increases, enhancing phagocytosis — the engulfing and destruction of pathogens
• Natural killer (NK) cell activity is supported — the first responders to viral-infected cells
• Cytokine production is modulated — not simply increased, but calibrated according to context
• T-cell responses may be influenced downstream through antigen presentation

A 2021 study (PMID: 33142551) isolated a hetero polysaccharide fraction (HEP-W) from Hericium erinaceus and tested it in cyclophosphamide-induced immunosuppression in mice — a model designed to mimic depleted immunity. HEP-W significantly enhanced immune organ index, splenocyte proliferation, NK cell activity, and IL-2 production, while improving macrophage phagocytosis. The researchers concluded that HEP-W could serve as a natural immunomodulatory agent.

A foundational structural study (PMID: 19809252) characterised a purified polysaccharide fraction (HEF-AP Fr II) as a laminarin-like beta-1,3-branched-beta-1,6-glucan and confirmed it upregulates macrophage function, triggering nitric oxide production and pro-inflammatory cytokine expression (IL-1β and TNF-β) — the hallmarks of an activated innate immune response.

The Modulation Principle: Why "Boosting" Gets It Wrong

Here is where most supplement marketing oversimplifies. "Boost your immune system" implies that more immune activity is always better. It is not.

An overactive immune system is the underlying mechanism in autoimmune conditions, chronic inflammation, and allergic responses. What you actually want is appropriate immune response: vigorous when defending against a genuine threat, restrained when the threat has passed.

This is precisely what the dual-compound profile of lion's mane appears to support. Research on erinacine C (PMID: 31547327) demonstrated that this terpenoid compound reduced nitric oxide production through downregulation of NF-κB and activation of the Nrf2-mediated HO-1 pathway in microglial cells. In plain terms: it helped calm an inflammatory immune response without suppressing the system entirely.

A 2015 study (PMID: 26559695) confirmed the ethyl acetate fraction of Hericium erinaceus significantly suppressed TNF-α and IL-6 production in LPS-stimulated macrophages through inhibition of TLR4-JNK signalling — a specific anti-inflammatory pathway that is increasingly understood as a target in metabolic and inflammatory disease.

The same organism contains immune-stimulating beta-glucans and anti-inflammatory terpenoids. The net effect is not "more" or "less" immune activity — it is better-calibrated immune activity. That is The Modulation Principle.

The Gut–Immune Connection: Where 70% of Immunity Lives

Approximately 70% of your immune system resides in the gut-associated lymphoid tissue (GALT) — a network of immune cells lining the gastrointestinal tract. This is not a wellness talking point; it is established immunology. And it represents one of the strongest pathways through which lion's mane may influence immune function.

A 2017 study published in Oncotarget (PMID: 29156761) tested Hericium erinaceus extracts in rats with inflammatory bowel disease induced by TNBS enema. The polysaccharide fraction demonstrated prebiotic-like effects — feeding beneficial gut bacteria — while the alcoholic extract showed bactericidin-like and immunomodulatory effects. Together, the extracts increased Foxp3 and IL-10 (immune regulators), decreased NF-κB and TNF-α (pro-inflammatory signals), and activated T-cells. Gut microbiota composition shifted significantly towards a healthier profile.

A 2018 study (PMID: 29677563) examined the polysaccharide fraction specifically in DSS-induced colitis in mice. Results showed suppression of IL-6, IL-1β, and TNF-α; blockage of NF-κB phosphorylation; reversal of gut dysbiosis; and maintenance of intestinal barrier integrity. The NF-κB pathway is a master regulator of inflammatory response — blocking its dysregulated activation is a genuine mechanism, not marketing language.

The most recent evidence comes from a 2026 study published in International Journal of Biological Macromolecules (PMID: 41819322), which investigated a commercially relevant beta-glucan-rich hot-water extract of Hericium erinaceus. In RAW 264.7 macrophages, it suppressed LPS-induced nitric oxide and pro-inflammatory cytokines (IL-6, MCP-1) without cytotoxicity. In DSS-stimulated colitis mice, it improved disease activity and colon length, normalised serum cytokines and immunoglobulins, and selectively remodelled inflammation-related microbial populations. Critically, this was tested with a commercially relevant extract — directly applicable to supplementation.

Organic Lion's Mane Mushroom Powder

Dual-extracted (water + ethanol), 10:1 concentration, 31.7% beta-glucans confirmed by COA, 100% fruiting body, Di Tao sourced, ACO certified organic.

View Product

Anti-Inflammatory Mechanisms: The Chronic Inflammation Problem

Chronic low-grade inflammation — sometimes called "inflammaging" — is increasingly recognised as a driver of immune decline, metabolic dysfunction, and accelerated ageing. Unlike acute inflammation (which resolves), chronic inflammation is a persistent background signal that wears the immune system down over years.

Lion's mane operates on several anti-inflammatory pathways simultaneously:

• NF-κB inhibition: Multiple studies confirm that lion's mane compounds — both polysaccharides and erinacines — reduce NF-κB activation, a central switch in the inflammatory response
• TLR4-JNK pathway inhibition: The 2015 macrophage study (PMID: 26559695) identified this as a specific mechanism for TNF-α and IL-6 suppression
• Nrf2-HO-1 pathway activation: Erinacine C activates this cytoprotective pathway, which counterbalances oxidative stress-driven inflammation (PMID: 31547327)
• Cytokine balance restoration: Across multiple IBD models, lion's mane consistently increases anti-inflammatory IL-10 while reducing pro-inflammatory TNF-α and IL-1β

A 2023 ex vivo study published in Frontiers in Immunology (PMID: 37465689) tested a nutraceutical compound containing Hericium erinaceus, berberine, and quercetin in tissue samples from inflammatory bowel disease patients. At 120 and 180 minutes post-incubation, COX-2 and TNF-α gene and protein expression progressively decreased, while the anti-inflammatory cytokine IL-10 showed a progressive increase. This is the closest available human tissue evidence for lion's mane's anti-inflammatory profile.

Seasonal Immunity: What Lion's Mane Can and Cannot Do

There are no clinical trials testing lion's mane against cold and flu outcomes with immune endpoints as the primary measure. The human evidence is limited compared to the preclinical data: the 28 human studies address related markers — inflammatory cytokines, cognitive outcomes, gut health — but none specifically measure "did you get fewer colds." Most research into lion's mane and immune defence was conducted in animal models or in vitro. That is worth stating clearly.

What the mechanistic evidence does support:

• Macrophage and NK cell priming through Dectin-1 activation — improving first-response capacity
• Gut barrier integrity maintenance — a compromised gut epithelium is a known vulnerability to pathogen entry
• Microbiome modulation towards a more anti-inflammatory profile — which indirectly supports GALT function
• Reduction of chronic background inflammation — freeing up immune resources for genuine threats

What lion's mane does not appear to do: directly kill pathogens, provide rapid immune stimulation comparable to echinacea or high-dose vitamin C, or produce measurable immune effects in a single dose.

The strongest practical case for lion's mane in seasonal immunity is as part of a consistent daily stack during high-exposure periods — not as a rescue intervention once symptoms appear.

Decision Engine: Is Lion's Mane Right for Your Immune Goals?

Honest Limitations: Where the Evidence Stops

Transparency is fundamental to our approach. The evidence for lion's mane and immunity has real and significant gaps that are worth stating plainly:

• No RCTs with immune endpoints as primary outcomes. The 28 human studies in the database address related markers — cytokines, cognitive outcomes, gut health — but no randomised controlled trial has been designed with immune function as the primary endpoint. This is a meaningful gap.
• No Cochrane systematic review exists for lion's mane in any health context. A Cochrane review would require pooling multiple RCTs, and those RCTs do not yet exist for immunity.
• Most immune-specific data involves animal studies and in vitro cell models, not human trials. The human evidence for lion's mane is limited relative to the prepreliminary research, and is concentrated in cognitive outcomes, not immune outcomes. Most of the studies cited in this article are animal studies or in vitro experiments. When we cite them, it is to explain the mechanism — not to claim proven human outcomes.
• Some studies showed no significant effect on certain immune markers in isolation, or results varied across extraction methods and polysaccharide fractions. Inconsistent findings across fractions are a recurring limitation noted in review literature (PMID: 41306342).
• EFSA beta-glucan health claims apply only to oat and barley sources. There is insufficient evidence in the EFSA framework to grant equivalent claims for mushroom-derived beta-glucans, regardless of structural similarities.
• FSANZ has no permitted health claims for lion's mane in Australia. All statements must be framed as traditional use or emerging research — not therapeutic claims.

A GOOD evidence grade across 215 studies represents a substantial body of mechanistic and observational data. However, we are precise about the difference between strong mechanistic plausibility and proven clinical outcomes in humans. The gut-immune axis evidence is the most translatable; the innate immune activation data is robust but largely preclinical. More research is needed before human immune claims can be made with clinical confidence.

Why Extraction Method Determines Everything

The Modulation Principle — the dual capacity to upregulate and downregulate immune activity — only functions if both compound families are present. This is entirely a function of extraction method.

Hot water extraction pulls the beta-glucan polysaccharides (our COA: 31.7% beta-glucans, exceeding our ≥30% specification). Ethanol extraction accesses the fat-soluble erinacines and hericenones that water cannot dissolve. A water-only extract gets half the bioactive profile. Our dual extraction uses a 10:1 concentration ratio to produce a potent, standardised powder.

Fruiting body versus mycelium also matters significantly. Mycelium grown on grain substrate (the most common low-cost approach) introduces cereal starch contamination, diluting the mushroom content. Our lion's mane is 100% fruiting body — no mycelium, no grain filler, no starch padding. This is not a marketing distinction. Standard testing for beta-glucan content distinguishes real mushroom material from substrate starch.

We source Di Tao from China, where Hericium erinaceus has been cultivated for centuries in ecologically appropriate conditions. Every batch is ACO certified organic and third-party tested before release.

Frequently Asked Questions

Conclusion

Lion's mane is not a one-dimensional brain supplement. The 215 immune-related studies in the literature describe a compound operating across the innate immune system, the inflammatory cascade, and the gut-immune axis simultaneously.

The Modulation Principle — the dual capacity to upregulate immune defences and downregulate excessive inflammation — is what distinguishes lion's mane from simple immune stimulants. It is not about pushing harder. It is about calibrating better.

The mechanisms are well-characterised: Dectin-1-mediated macrophage and NK cell activation, NF-κB inhibition via erinacines, TLR4-JNK pathway suppression, gut microbiome rebalancing, and gut barrier integrity support. The evidence grade is GOOD — substantial and mechanistically coherent — but honest gaps remain. We need human RCTs with immune-specific endpoints. The gut-immune axis studies are the most translatable; the innate immune activation data is robust but largely preclinical.

For Australians seeking a long-term approach to immune resilience — not a quick seasonal fix — lion's mane represents a well-supported, TGA-compliant option worth considering. As with all supplements, consistency and quality of product matter enormously. Extraction method, beta-glucan content, and sourcing are not marketing details. They are the determinants of whether the biology described in this article actually applies to what is in the jar.

Explore further: Lion's Mane for Gut Health | Lion's Mane Buying Guide | Complete Benefits Guide

Continue Your Research

• Lion's Mane for Athletes: Performance, Recovery, and Honest Expectations
• Lion's Mane for Energy: Not a Stimulant, Something Different
• Lion's Mane for Pain: What the Pre-Clinical Research Shows
• Lion's Mane Dosage Guide: Clinical Trial Doses, Extract Conversions & Timing
• Lion's Mane Side Effects: Safety Profile Review
• Lion's Mane for ADHD and Focus: What the Research Actually Shows
• Lion's Mane for Anxiety: What the Research Actually Shows
• Lion's Mane for Skin: The Ergothioneine Advantage

← Back to Lion's Mane Research Hub